WiseGuyReports published new report, titled “Global Biologics Drug Discovery Market”
The drug discovery process comprises of iterative cycles between chemistry and biology. Natural sources serve as compound of interest in drug discovery for the treatment of many diseases. Over 20 new drugs were launched in the market between 2000-2005, originated from terrestrial plants, terrestrial microorganisms, marine organisms and terrestrial vertebrates and invertebrates.
The drug discovery procedure is long, arduous and costly, which has encouraged outsourcing in the drug discovery field. The drug discovery market is driven by the factors such as rising geriatric population, increase in investments in this field due to the advancements in the field of biotechnology, microbiology, genetics and structural biology. However, slow pace of formulating the drug discovery projects by the government hinders the biologics drug discovery market.
For instance, the main purpose of Novartis compound collection enhancement project for the compilation of a comprehensive chemogenomics drug discovery screening collection is to supply the Novartis drug discovery pipeline with hit to lead drugs/compounds for present and future portfolios of drug discovery programs. There are many drug discovery approaches targeting the cancerous cells by Novartis Institutes for Biomedical Research, Switzerland and Cambridge.
- By Technology
o DNA Microarrays
o Protein Microarrays
o High-throughput screening
o Mass Spectrometry
o Gel Electrophoresis
o Protein and Nucleic Acid Isolation
o Other technologies
- By End User
o Outsourcing (Contract Research Organization)
o Insourcing (Within the Organization)
Growth Drivers and Challenges
The major driving factors of biologics drug discovery market are high prevalence of genetic disorders, nervous system disorders, diabetes and cardiovascular diseases along with advancement in the field of biotechnology, genetics, structural biology and molecular biology. Increase in health expenditure, highly robust, upsurge in the discovery of therapeutics ventures and populated drug pipeline for novel drugs. Furthermore, patents of drugs expire that tends to make the lucrative market for the existing players. In US and Canada biologics drug discovery market is high due to promising healthy potential returns on investments and high-income population.
However, shift from traditional methods to personalized drug discovery is hindering the global biologics drug discovery market. Delay in government approval for drug discovery and huge investment favoring the shift from market branded drugs to generic drugs are the challenges faced by biologics drug discovery market. Lower profit margins of pharmaceutical companies which are due to the huge investments made on drug discovery and consume time hampers the biologics drug discovery market.
Market Size and Forecast
The global market for biologics drug discovery market reached nearly USD 56.6 billion in 2016 and is expected to reach USD 140.9 billion by 2024 at the CAGR of 12% over the forecast period.
High throughput screening is widely adopted drug discovery technology owing to the fact that it enables portfolio construction of biologically relevant compounds quickly.
The global biologics drug discovery market North America holds the largest market share in the global drug discovery market owing to the concentration of world’s leading pharmaceutical companies. The US and Canadian Government have formulated encouraging policies for the investors to research and develop new drugs.
Key Market Players
- Johnson and Johnson
o Business Strategy
o Product Portfolio
o SWOT Analysis
• Bayer AG
• AstraZeneca PLC
• Pfizer Inc.
• Merck & Co. Inc.
• Boehringer Ingelheim Inc.
• Glaxosmithkline LLC
• Eli Lily
• Roche Holding AG.
• Charles River Laboratories
• Albany Molecular Research Inc.
• Boehringer Ingelheim GmBh
• Jubilant Biosys
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.
Email Us at : firstname.lastname@example.org
Reach Us at : +1 339 368 6938 (US) +44 208 133 9349 (US)